Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab response monitoring in metastatic colorectal cancer
ISRCTN75334801Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Heidelberg University. Primary endpoint: Prognostic relevance of delta-SUV for early clinical response. Started Jan 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN75334801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN75334801.